schorpion

[schorpion @schoorperion]

@sharkbiotech regeneron!

[schorpion @schoorperion]

@juliaskripkaser Sometimes PI3K is mutated and then alpelisib expanded access would be an option. DNA seq is recommended

[schorpion @schoorperion]

@biostockguru They also started PUR1800 phase 1 in COPD with no PR yet https://t.co/cZkIehdGSZ

[schorpion @schoorperion]

@RamsCharts What about prqr? Sudden volume and price increase since last week

[schorpion @schoorperion]

@portefeuillefun Institution buying or manipulation (similar move for achieve life sciences yesterday)

[schorpion @schoorperion]

@Kevin_W81 English bulldogs 😍

[schorpion @schoorperion]

@bigpharmaguy Zeno failed in breast cancer as well. Hope it works in pancreatic cancer though, high unmet need

[schorpion @schoorperion]

@bigpharmaguy Elevation oncology with seribantumab and rain therapeutics with tarloxotinib are both in the clinic for NRG1 fusion driven tumors

[schorpion @schoorperion]

@Bios_n_Techs @avidresearch Maybe muscle deterioration is irreparably high at higher ages. DMD patients can be in a wheelchair when 10 years old. Wonder what outcomes would have been with a study in babies like AVXS-101 did

[schorpion @schoorperion]

@Pharmdca Safety data already established for Dexdor and this trial was not powered for efficacy data, so nothing really special imo

[schorpion @schoorperion]

@portefeuillefun @AAMortazavi That would only happen when Aat van Herk pushes for an aggressive exitstrategy and Onno retires. And Onnos dream is to create drugs for patients and I think he doesnt feel so good about filgo anymore

[schorpion @schoorperion]

@gcbioinv 4 responses, 2 per cohort